Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients

HIV Clinical Trials

Volumn 9, Issue 1, 2008, Pages 1-10

  Murphy, Robert L ^a   Da Silva, Barbara A ^b,g   Hicks, Charles B ^c   Eron, Joseph J ^d   Gulick, Roy M ^e   Thompson, Melanie A ^f   McMillan, Florence ^b   King, Martin S ^b   Hanna, George J ^b   Brun, Scott C ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ABBOTT LABORATORIES   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f AIDS Research Consortium of Atlanta   (United States)

^g Building AP30 3 ^*  (United States)

Author keywords

Antiretroviral na ve; Lopinavir ritonavir; Metabolic; Tolerability; Triglycerides

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN C3; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LEPTIN; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DETOXIFICATION; DIARRHEA; DRUG EFFICACY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOLYMPHOMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; STAVUDINE;

EID: 38949178107     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0901-1     Document Type: Article

References (46)

1. Cameron D, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351:543-549.
2. Gulick R, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Eng J Med. 1997;337:734-739.
3. Palella F, Delaney K, Moorman A, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med. 1998;338:853-860.
4. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. Available at: http://AID-Sinfo.nih.gov
5. Gazzard B, BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005). HIV Med. 2005;6(Suppl 2):1-61.
6. Albrecht M, Bosch RJ, Liou SH, Katzenstein D. ACTG 364: efficacy of nelfinavir (NFV) and/or efavirenz (EFV) in combination with new NRTIs in nucleoside experienced subjects: week 144 results. In: Program and abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle. Abstract 425 W.
7. Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, et al. Durable viral suppression on EFV-based HAART: 168 weeks of follow-up [abstract]. XV International AIDS Conference; July 2004; Bangkok, Thailand.
8. Gulick R, Meibohm A, Havlir D, Eron JJ, Morley A, Chodakewitz JA, et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS. 2003;17:2345-2349.
9. Albrecht M, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Eng J Med. 2001;345:398-407.
10. Gallant J, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
11. Sham H, Kempf D, Molla A, Marsh KC, Kumar GN, Chen CM, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.
12. Eron J, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
13. Molla A, Vasavanonda S, Kumar G, Sham HL, Johnson M, Grabowski B, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology. 1998;250:255-262.
14. Benson A, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
15. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
16. Dragsted U, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005;10:735-743.
17. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694.
18. Johnson M, Grinsztejn B, Rodriguez C, Coco J, Dejesus E, Lazzarin A, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711-718.
19. Pollard R, Thompson M, Hicks C, Grinsztejn B, Horban A, King M, et al. Phase 3 comparison of lopinavir/ritonavir vs. investigator-selected protease inhibitors in single Pl-experienced, NNRTI-naive patients: 48-week results of study M98-888. 7th International Congress on Drug Therapy in HIV Infection; November 2004; Glasgow.
20. Shafran S, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005;6:421-425.
21. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
22. Gallant J, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Eng J Med. 2006;354:251-260.
23. van der Valk M, Gisolf EH, Reiss P, Wit FWNM, Japour A, Weverling AGJ, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847-855.
24. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease-inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-32.
25. Lafeuillade A, Jolly P, Chadapaud S, Hittinger G, Lambry V, Philip G. Evolution of lipid abnormalities in patients switched from stavudine- to tenofovir-containing regimens. J Acquir Immune Defic Syndr. 2003;33:544-546.
26. Domingo P, Labarga P, Palacios R, Guerro MF, Terron JA, Elias MJ, et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS. 2004;18:1475-1478.
27. Garcia-Benayas T, Blanco F, Alcolea A, Cruz JJ, Gonzalez-Lahoz J, Soriano V. Short communication: benefits in the lipid profile after substitution of abacavir for stavudine: a 48-week prospective study. AIDS Res Hum Retroviruses. 2004;20:1289-1292.
28. Shlay J, Visnegarwala F, Bartsch G, Wang J, Peng G, El-Sadr WM, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147-155.
29. Martin A, Smith D, Carr A, Hoy J, Chuah J, Mallal S, et al. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study). HIV Clin Trials. 2004;5:192-200.
30. Murphy R, Brun S, Hicks C, Eron, JJ, Gulick R, King M, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:1-9.
31. Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18:775-779.
32. Division of Drug and Biological Products Experience, Food and Drug Administration. Coding Symbols for Thesaurus of Adverse Reaction Terms. 5th ed. Rockville, MD: US Food and Drug Administration; 1996.
33. Gathe J, Chu A, Yuen N, Petersen A. Durability of nelfinavir combination therapy after 4 years: 3 year extension data from Agouron Study 511. In: Program and abstracts of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; October 2001 ; Athens. Abstract LB10.
34. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Eng J Med. 1999;341:1865-1873.
35. Saag M, Tebas, P, Sension, M, Conant, M, Myers, R, Chapman, SK, et al. Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron Study 511). AIDS. 2001;15:1971-1978.
36. Conn J, Tremblay M, Batal R, Jacques H, Rodriguez C, Steiner G, et al. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 2004;177:137-145.
37. Llibre J, Domingo P, Palacios R, Santos J, Perez-Elias MJ, Sanchez-de la Rosa R, et al. Sustained improvement of dyslipidemia in HAART-treated patients replacing stauvudine with tenofovir DF-48 weeks results. AIDS. 2006;20:1407-1414.
38. Wallace T, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002;19:527-534.
39. Abbasi F, Reaven GM. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans. Metabolism. 2002;51:235-237.
40. Lihn A, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev. 2005;6:13-21.
41. Brown T, Li X, Cole SR, Kingsley LA, Palella FJ, Riddler SA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375-1383.
42. Nagy G, Tsiodras S, Martin LD, Avihingsanon A, Gavrila A, Hsu WC, et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis. 2003;36:795-802.
43. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: structure, function and biology. Vitam Horm. 2005;71:345-372.
44. Wunder D, Bersinger NA, Fux C, Weber R, Bernasconi E, Cavassini M, et al. Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS. 2005;19:1837-1842.
45. Graham I, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-1781.
46. Ridker P. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol. 2003;92(suppl):17K-22K.